Immunomodulatory Effects of Bcg in Patients with Recurrent Respiratory Papillomatosis / Иммуномоделирующие Эффекты Всg У Пациентов С Рецидивирующим Респираторным Папилломатозом

Autor:	Maria Nikolova, Ivan J. Chalakov, Tsvetelina R. Stefanova, Toma Avramov, Mariya Muhtarova, Evelina K. Vetskova
Rok vydání:	2013
Předmět:	Cellular immunity business.industry medicine.medical_treatment T cell FOXP3 General Medicine Interleukin 10 Cytokine medicine.anatomical_structure Immunology Medicine Interferon gamma Recurrent Respiratory Papillomatosis business CD8 medicine.drug
Zdroj:	Folia Medica. 55:49-54
ISSN:	1314-2143 0204-8043
DOI:	10.2478/folmed-2013-0005
Popis:	BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a rare manifestation of human papilloma virus (HPV) infection with extremely high relapse frequency, poorly understood immunopathogenesis, and lack of efficient treatment. Immunotherapy with Calgevax (BCG) in combination with CO2 surgery significantly improves the outcome of RRP. The present study investigates cellular immunity parameters in RRP patients, and the effects of 20-month Calgevax immunomodulation. MATERIALS AND METHODS: RRP patients (n = 15) subjected to combined therapy were tested before, 6, 12 and 20 months after the start of immunomodulation. Absolute counts and percentage of T, B and NK cells, effector Tc1 (CD8 + IFNγ+); Th1 (CD4+IFNγ+), Th17 (CD4+IL-17+) and regulatory (CD4+FoxP3+) T lymphocytes, as well as the in vitro stimulated secretion of IL-2, IL-4, IL-5, IL-10, IFNγ and TNFα were determined by flow cytometry (FACSCanto II, BD). RESULTS: While no significant changes were detected in the circulating T, B and NK subsets, RRP patients presented increased proportions of Tc1, Th1 and Th17 cells, and significantly reduced IFNγ/IL-4 and IFNγ/IL-10 ratios as compared to healthy controls (15% vs. 8%), (58 vs. 139 and 15 vs. 26, respectively), p < 0.05 for all comparisons. Increased Treg (9% vs. 4%), and decreased Th17 effectors share (0.7% vs. 0.4%) were observed at 12 months, while IFNγ/IL-4 and IFNγ/IL-10 ratios were restored after 20 months of Calgevax application. CONCLUSIONS: Antiviral response closely depends on cytokine background. Calgevax potentiates Treg differentiation at the expense of proinflammatory Th17, limits hyperactivation and virus-specific T cell clones depletion, and restores a Th1 cytokine background.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c04a54f099fdca4340987451ea455f13 https://doi.org/10.2478/folmed-2013-0005 Zobrazit plný text záznamu